Summit Therapeutics Reports Updated Overall Survival Data In Phase III HARMONi Trial Of Ivonescimab Plus Chemo Showing Improved OS Trend; PDUFA Goal Action Date November 14

Loading news article.

Summit Therapeutics Reports Updated Overall Survival Data In Phase III HARMONi Trial Of Ivonescimab Plus Chemo Showing Improved OS Trend; PDUFA Goal Action Date November 14 | WAPE

Summit Therapeutics Reports Updated Overall Survival Data In Phase III HARMONi Trial Of Ivonescimab Plus Chemo Showing Improved OS Trend; PDUFA Goal Action Date November 14

Article summary

Related companies

Comments —